PATENTS

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: William M. Hammesfahr

S.N.: 09/841,546 GROUP ART UNIT 3737

FILED: 04/23/2001 EXAMINER: Ramirez, John F.

FOR: A TITRATION SYSTEM FOR TREATING ATTY. DOC. 2087.1

CEREBRAL VASOSPASMS

MAIL STOP APPEAL BRIEF - PATENTS

COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

Sir:

### APPLICANT'S BRIEF ON APPEAL

In response to the Notice of Non-Compliant Appeal Brief, dated June 26, 2008, applicant submits three copies of the amended Claims Appendix in substitution of the previously filed Claims Appendix which contained a typographical error in Claim 43.

Respectfully submitted,

/Herbert William Larson/

Herbert W. Larson Registration No. 21008 Attorney for Applicant LARSON & LARSON, PA 11199 69th Street North Largo, FL 33773 (727) 546-060 Phone (727) 545-1595 Fax

Customer No. 22497

1

# VIII. CLAIMS APPENDIX

- 38. A titration system for diagnosing and treating a disease caused at least partially by insufficient cerebral perfusion, comprising in combination:
  - a flow measuring device to test for cerebral vasospasm, a dosage device which administers a vasospasm-reducing dosage of a medicine selected from the empirical group of medications which have the common characteristic of causing smooth muscle relaxation and/or which reduce pulmonary capillary wedge pressure, and said dosage device being adjustable over time to titrate said dosage in response to said testing to increase, decrease or substitute another medicine to minimize occurrence and severity of said vasospam.
- 39. A system according to Claim 38 wherein the flow measuring device comprises transcranial Doppler measuring means.
- 40. A system according to Claim 38 wherein the dosage device comprises means for delivering a vasodilator selected from the group comprising Nitroglycerin in pill, patch, ointment, cream, inhaler, spray and other forms, Nitroglycerin equivalents and substitutes, comprising p.o. clonidine, israpidine, hydrazine, nifedipine, and/or other medicines selected from the empirical

group of medications which have the common characteristic of causing smooth muscle relaxation and/or which systemically reduce pulmonary capillary wedge pressure, and combinations of the foregoing.

- 41. A system according to Claim 38 wherein the flow measuring device comprises transcranial Doppler measuring means and the dosage device comprises transdermal, inhaler, spray and other forms of vasodilator selected from the group consisting of Nitroglycerin, Nitroglycerin equivalents and substitutes, p.o. clonidine, isradipine, hydrazine, nifedipine, and/or medicines selected from the empirical group of medications which have the common characteristic of causing smooth muscle relaxation and/or which systemically reduce pulmonary capillary wedge pressure, and combinations of the foregoing.
- 42. A system according to Claim 41 wherein the delivery device comprises means for delivering a vasodilator selected from the group comprising Nitroglycerin in pill, patch, ointment or cream form.
- 43. A system according to Claim [46] 41 wherein the delivery system is adapted for transdermal delivery.

44. A system according to Claim 38 wherein the delivery system is adapted for the adjusting of the dosage device over time within the range of about 0.02 to 20 milligrams per day (Nitroglycerin equivalent) of vasodilator.

# VIII. CLAIMS APPENDIX

- 38. A titration system for diagnosing and treating a disease caused at least partially by insufficient cerebral perfusion, comprising in combination:
  - a flow measuring device to test for cerebral vasospasm, a dosage device which administers a vasospasm-reducing dosage of a medicine selected from the empirical group of medications which have the common characteristic of causing smooth muscle relaxation and/or which reduce pulmonary capillary wedge pressure, and said dosage device being adjustable over time to titrate said dosage in response to said testing to increase, decrease or substitute another medicine to minimize occurrence and severity of said vasospam.
- 39. A system according to Claim 38 wherein the flow measuring device comprises transcranial Doppler measuring means.
- 40. A system according to Claim 38 wherein the dosage device comprises means for delivering a vasodilator selected from the group comprising Nitroglycerin in pill, patch, ointment, cream, inhaler, spray and other forms, Nitroglycerin equivalents and substitutes, comprising p.o. clonidine, israpidine, hydrazine, nifedipine, and/or other medicines selected from the empirical

group of medications which have the common characteristic of causing smooth muscle relaxation and/or which systemically reduce pulmonary capillary wedge pressure, and combinations of the foregoing.

- 41. A system according to Claim 38 wherein the flow measuring device comprises transcranial Doppler measuring means and the dosage device comprises transdermal, inhaler, spray and other forms of vasodilator selected from the group consisting of Nitroglycerin, Nitroglycerin equivalents and substitutes, p.o. clonidine, isradipine, hydrazine, nifedipine, and/or medicines selected from the empirical group of medications which have the common characteristic of causing smooth muscle relaxation and/or which systemically reduce pulmonary capillary wedge pressure, and combinations of the foregoing.
- 42. A system according to Claim 41 wherein the delivery device comprises means for delivering a vasodilator selected from the group comprising Nitroglycerin in pill, patch, ointment or cream form.
- 43. A system according to Claim [46] 41 wherein the delivery system is adapted for transdermal delivery.

44. A system according to Claim 38 wherein the delivery system is adapted for the adjusting of the dosage device over time within the range of about 0.02 to 20 milligrams per day (Nitroglycerin equivalent) of vasodilator.

# VIII. CLAIMS APPENDIX

- 38. A titration system for diagnosing and treating a disease caused at least partially by insufficient cerebral perfusion, comprising in combination:
  - a flow measuring device to test for cerebral vasospasm, a dosage device which administers a vasospasm-reducing dosage of a medicine selected from the empirical group of medications which have the common characteristic of causing smooth muscle relaxation and/or which reduce pulmonary capillary wedge pressure, and said dosage device being adjustable over time to titrate said dosage in response to said testing to increase, decrease or substitute another medicine to minimize occurrence and severity of said vasospam.
- 39. A system according to Claim 38 wherein the flow measuring device comprises transcranial Doppler measuring means.
- 40. A system according to Claim 38 wherein the dosage device comprises means for delivering a vasodilator selected from the group comprising Nitroglycerin in pill, patch, ointment, cream, inhaler, spray and other forms, Nitroglycerin equivalents and substitutes, comprising p.o. clonidine, israpidine, hydrazine, nifedipine, and/or other medicines selected from the empirical

group of medications which have the common characteristic of causing smooth muscle relaxation and/or which systemically reduce pulmonary capillary wedge pressure, and combinations of the foregoing.

- 41. A system according to Claim 38 wherein the flow measuring device comprises transcranial Doppler measuring means and the dosage device comprises transdermal, inhaler, spray and other forms of vasodilator selected from the group consisting of Nitroglycerin, Nitroglycerin equivalents and substitutes, p.o. clonidine, isradipine, hydrazine, nifedipine, and/or medicines selected from the empirical group of medications which have the common characteristic of causing smooth muscle relaxation and/or which systemically reduce pulmonary capillary wedge pressure, and combinations of the foregoing.
- 42. A system according to Claim 41 wherein the delivery device comprises means for delivering a vasodilator selected from the group comprising Nitroglycerin in pill, patch, ointment or cream form.
- 43. A system according to Claim [46] 41 wherein the delivery system is adapted for transdermal delivery.

44. A system according to Claim 38 wherein the delivery system is adapted for the adjusting of the dosage device over time within the range of about 0.02 to 20 milligrams per day (Nitroglycerin equivalent) of vasodilator.